Fig. 1
From: Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene
a IC50 of CBFA2T3-GLIS2 and negative cell lines 72 h after GANT61 exposure. b Dose-response curves after 72 h of GANT61 treatment of primary cells derived from patients with acute myeloid leukemia (AML) either positive or negative for CBFA2T3-GLIS2 fusion gene. *p < 0.05 c Flow cytometric analysis of Annexin V FITC/PI-stained AML cell lines treated for 24 h with 20 μM of GANT61. The percentages of early apoptotic cells (Annexin V FITC+/PI−, lower right quadrant) and late apoptotic/necrotic cells (Annexin V FITC+/PI+, upper right quadrant) are indicated. NT sample treated with vehicle alone (DMSO). d Cell cycle analysis. Flow cytometric analysis of PI-stained AML cell lines carrying the CBFA2T3-GLIS2 fusion gene after 48 h of treatment with GANT61. NT sample treated with vehicle alone (DMSO)